While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tri ...

Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 29:Ultrapar Participações S.A. (UGP) : This energy and infrastructure company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 31.8% over the last 60 days.Ultrapar Participações has a price-to-earnings ratio (P/E) of 19.66 compared with 22.57 for the S&P. The company possesses a Value Score of B.Honda Motor Co., Ltd. (HMC) : This autom ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET Company Participants Christopher James - VP of Investor Relations Joseph Ciaffoni - President and CEO Colleen Tupper - EVP and CFO Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Serge Belanger - Needham & Co. Leszek Sulewski - Truist Securities Oren Livnat - H.C. Wainwright Operator Greetings, and welcome to the Collegium Pharmaceutical Fourth Quarte ...

Life-Threatening Respiratory Depression Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of BELBUCA and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. See full prescribing information, including Boxed Warning on Addiction, Abuse and Misuse, and Other Serious Risks at ...

For the quarter ended December 2023, Collegium Pharmaceutical (COLL) reported revenue of $149.75 million, up 15.5% over the same period last year. EPS came in at $1.58, compared to $1.09 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $147.66 million, representing a surprise of +1.41%. The company delivered an EPS surprise of +18.80%, with the consensus EPS estimate being $1.33.While investors closely watch year-over-year changes in headline numbers -- revenue and ea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State or other jurisdiction of incorporation or o ...

Exhibit 99.1 Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – ...

STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Collegium Pharmaceutical (COLL) , which belongs to the Zacks Medical - Drugs industry.This specialty pharmaceutical company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 5.67%.For the last reported quarter, Collegium Pharmaceutic ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - President and CEO Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Tim Lugo - William Blair Serge Belanger - Needham & Company Les Sulewski - Truist Securities Operator Greetings, and welcome to Collegium Pharmaceuticals Th ...